214 related articles for article (PubMed ID: 30486661)
1. Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.
Ramacciotti E; Aguiar VCR; Júnior VC; Casella IB; Zerati AE; Fareed J
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):340S-349S. PubMed ID: 30486661
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
3. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban (LIXIANA
Bottino R; Carbone A; Liccardo B; D'Andrea A; Rago A; Papa AA; Spaccarotella C; Golino P; Nigro G; Russo V
Future Cardiol; 2021 Aug; 17(5):779-791. PubMed ID: 33231106
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
6. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.
De Caterina R; Ageno W; Boriani G; Colonna P; Ghirarduzzi A; Patti G; Rossini R; Rubboli A; Schinco P; Agnelli G
Adv Ther; 2017 Mar; 34(3):620-637. PubMed ID: 28194578
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Ikeda S; Koga S; Yamagata Y; Eguchi M; Sato D; Muroya T; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
J Cardiol; 2018 Aug; 72(2):120-127. PubMed ID: 29661489
[TBL] [Abstract][Full Text] [Related]
10. The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients.
Abdel-Razeq H; Finianos A; Taher AT
Expert Rev Hematol; 2018 Jun; 11(6):487-494. PubMed ID: 29791257
[TBL] [Abstract][Full Text] [Related]
11. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
[TBL] [Abstract][Full Text] [Related]
12. Real-life experience of edoxaban treatment for venous thromboembolism (VTE)/pulmonary embolism (PE) in patients with isolated positive Lupus Anticoagulant (LAC) during the COVID-19 pandemic lockdown in Italy.
Puccetti L; Sammartano V; Calzoni P; Bacchiarri F; Santoni A; Fineschi D; Bocchia M
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):54-58. PubMed ID: 35049019
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
14. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Vanassche T; Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MPA; Chen CZ; Cohen AT; Grosso MA; Medina AP; Mercuri MF; Winters SM; Zhang G; Weitz JI; Raskob GE; Büller HR
Thromb Res; 2018 Feb; 162():7-14. PubMed ID: 29248859
[TBL] [Abstract][Full Text] [Related]
15. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
[TBL] [Abstract][Full Text] [Related]
16. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
[TBL] [Abstract][Full Text] [Related]
17. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger M
Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Shirley M; Dhillon S
Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]